Solstice Oncology secures $225m to drive porustobart's development for cancer

Solstice Oncology has secured $225m to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors. Porustobart is a second-generation, Fc-enhanced CTLA-4 antibody developed by Harbour BioMed. Credit: T. Schneider / Shutterstock.com. Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. LOA and PTSR Model FPI-1434 in Head…

Source: Pharmaceutical Technology